Seeking Alpha Portfolio App for iPad
Dividends & Income
View as an RSS Feed
View bullmarket2222's Comments
Glu Mobile's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Everything looks solid moving forward. The short position is my major concern. It's either a death trap or a major catalyst for the stock. Right now I see it as a major catalyst. I want to say thanks to Seeking Alpha for providing the transcript.
Oct 17 02:06 AM
Link to Comment
Rosetta Genomics: What Happens When The Music Ends?
To value ROSG, I would look to how industry experts valued the competitors at some point or another. This is what I have so far:
BioTheranostics (formerly AviaraDx)
CUP test: CancerType ID
Medicare coverage announced in mid-2011
Acquired by BioMerieux in 2008 for $60 million (before Medicare coverage)
CUP test: Tissue of Origin test
Medicare coverage in mid-2011
Series C financing of $30 million (typically for 15-20% of the company)
--- series C valuation happened after medicare coverage was announced
*** both of these tests originally cost somewhere between $3500-$4000. Medicare reimbursement is in the $2500 neighborhood. Very similar pricing to mets2.
So how might ROSG be valued? At least $60 mil (Aviara without Medicare coverage), and at most $200 mil (upper end of PathWork valuation). PathWork had a lot more literature on their test, was first-to-market and is FDA-approved (their first generation test). That's a broad range and reality probably lies at the lower-middle end of it. Still, with the current market cap at ~ $35 mil (~ 2.4 mil shares) and no fund raising for at least 16 months, ROSG should be a safe bet. However, form 6k did say 'Based on current operations'… if they hire more reps, the cash won't last nearly as long and dilution may occur.
Jun 11 07:08 AM
Link to Comment
The Opinion Leaders
Xignite quote data
© 2013 Seeking Alpha